The Top 5 Biosimilar Articles for the Week of April 29

Number 5: Despite current challenges in biosimilar market growth due to stakeholder disagreements, a recent commentary proposes that applying collective action theory can achieve widespread biosimilar market uptake by fostering collaboration for long-term benefits.

Number 4: The FDA has granted approval for Shanghai Henlius Biotech’s trastuzumab biosimilar, Hercessi (trastuzumab-strf; HLX02), for the treatment of HER2-positive breast cancer. The approval marks the sixth for a biosimilar referencing Herceptin (trastuzumab) and first overall for the company in the US.

Number 3: Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.

Number 2: High rates of biosimilar uptake in the American Oncology Network (AON) have saved the organization over $243 million between 2020 and 2023, according to Melody Chang, vice president of pharmacy operations at AON.

Number 1: A review article summarized the totality of evidence supporting the approval of the adalimumab biosimilar GP2017 (Hyrimoz; Sandoz) in the United States and Europe.

To read all of these articles and more, visit centerforbiosimilars.com.